AstraZeneca (AZN): UK Firm Set to Buy Pearl Therapeutics For $1.15 Billion+



UK's AstraZeneca is set to buy U.S. lung drug firm Pearl Therapeutics for up to $1.15 billion. The company is hoping to restore its fortunes after a string of late-stage research failures. It has also seen a number of big sellers fall out of patent, and stalwarts Nexium and Crestor are set to lose their crucial U.S. patent protection in 2014 and 2016 respectively.

The deal for U.S.-based Pearl Therapeutics will give Astra a stronger foothold in the market for lung treatments by giving it access to a potential new treatment for chronic obstructive pulmonary disease, which is currently in late-stage development. The takeover is a clear signal that the company’s new Chief Executive Pascal Soriot believes its respiratory business is a core growth area.

AstraZeneca has been suffering falling profits and sales as several of its blockbuster drugs, such as the anti-psychotic Seroquel and anti-cholesterol Crestor, have lost their patent protection, allowing cheaper generic drugs to enter the market.

Some industry analysts believe that LABA/LAMA inhalers are set to dominate future therapy for chronic obstructive pulmonary disease (COPD), which causes debilitating breathlessness and affects an estimated 210 million people worldwide.

Under the terms of the agreement, the British-Swedish pharmaceutical and biologics company will pay $560m up front and a further $450m dependent on specific development and regulatory milestones.

The pharmaceuticals Sales-related payments of up to a further $140m are payable it sales thresholds are met.

"Pearl has extraordinary research and clinical development teams that have successfully completed 10 clinical trials for our lead program," said Chuck Bramlage, chief executive officer for Pearl Therapeutics.  "We look forward to combining our skills and the global regulatory and commercial expertise at AstraZeneca to move PT003 and our other candidates towards market where they can reach millions of patients suffering from COPD."

Kevin Ferro, chairman of the Board of Pearl Therapeutics and chief executive of Vatera Healthcare Partners, Pearl's lead investor, said: “We have been impressed with AstraZeneca's expertise, focus and speed of execution and are delighted to be joining the group, a global leader in respiratory disease, as we believe that Pearl will be an excellent fit for its respiratory portfolio.”

Pearl's lead product, PT003, is a fixed dose combination of formoterol fumarate, a long-acting beta-2-agonist (LABA) and glycopyrrolate, a long-acting muscarinic antagonist (LAMA). It is in final-stage Phase III clinical trials.

The deal, which is expected to close in the third quarter of 2013, will have no impact on AstraZeneca’s financial guidance for the year, the company said.

The company is simplifying its drug development programme, cutting 5,000 jobs by 2016, and is looking to expand through acquisitions instead.

How much do you trust the information in this article?

Yassine Imrani

recently graduated from ESLSCA-PARIS-(master1) in business and management. I am a freelance political researcher/writer for a few websites, magazines and other types of media with experience in political and social analysis and have extensive knowledge in the field of political My areas of interest are international relations, politics, literature, cultural studies, and economics. Now I am trying to create a regional electronic network.

MORE FROM

Amid new revelations, here’s what we’ve learned about the Russian lawyer who met with Trump Jr.

The picture of Natalia Veselnitskaya is coming into clearer focus.

Republican Senator urges whoever leaked Russia/Sessions phone calls to release whole conversation

Sen. Chuck Grassley wants the person who leaked intelligence about Attorney General Jeff Sessions and Russian ambassador Sergey Kislyak to come forward with more information.

Donald Trump Jr. and Paul Manafort now to testify before Senate committee behind closed doors

Trump Jr. and Manafort have avoided a subpoena and will testify behind closed doors — for now.

Hope Hicks reportedly tried to rein Trump in during explosive ‘Times’ interview. It didn’t work.

The low-profile Trump Whisperer is one of the few in the president's orbit to enjoy job security.

Scaramucci once asked Obama if he’d be softer on Wall Street. It didn’t end well.

The exchange came during a CNBC town hall on the financial crisis, two years into Obama’s presidency.

Trump blasts Hilary Clinton, Comey and ‘Amazon Washington Post’ in tweet storm

He also defended Don Jr. and called Democrats "obstructionists" with "no ideas."

Amid new revelations, here’s what we’ve learned about the Russian lawyer who met with Trump Jr.

The picture of Natalia Veselnitskaya is coming into clearer focus.

Republican Senator urges whoever leaked Russia/Sessions phone calls to release whole conversation

Sen. Chuck Grassley wants the person who leaked intelligence about Attorney General Jeff Sessions and Russian ambassador Sergey Kislyak to come forward with more information.

Donald Trump Jr. and Paul Manafort now to testify before Senate committee behind closed doors

Trump Jr. and Manafort have avoided a subpoena and will testify behind closed doors — for now.

Hope Hicks reportedly tried to rein Trump in during explosive ‘Times’ interview. It didn’t work.

The low-profile Trump Whisperer is one of the few in the president's orbit to enjoy job security.

Scaramucci once asked Obama if he’d be softer on Wall Street. It didn’t end well.

The exchange came during a CNBC town hall on the financial crisis, two years into Obama’s presidency.

Trump blasts Hilary Clinton, Comey and ‘Amazon Washington Post’ in tweet storm

He also defended Don Jr. and called Democrats "obstructionists" with "no ideas."